SUMMARY: Invokana — first available in 2013 –is part of a new class of diabetes medications called Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, which also these drugs:
Invokamet — first available in 2014
Farxiga — first available in 2014
Xigduo XR — first available in 2014
Jardiance — first available in 2014
Glyxambi — first available in 2015
As some of you know, often the serious side effects of new drugs are not recognized until after FDA approval and they are used by a larger patient population than was observed or studied in the earlier clinical trials.
And this seems to be the case with Invokana, Farxiga, Jardiance, and these other new diabetes drugs, as there are now numerous adverse event report which associate them with these side effects:
• Diabetic Ketoacidosis (DKA), Ketoacidosis, or Ketosis
• Heart Attacks / Myocardial Infarctions (MI)
• Ischemic Stroke / Cerebral Vascular Accident (CVA)
• Kidney Damage / Renal Failure
• Heart Failure
And, in fact, reports of side effects related to Invokana, Farxiga, and Jardiance have gotten the attention of the FDA and other drug regulators.
With these investigations by drug regulators there are, also, investigations by drug injury lawyers into possible lawsuits for people with Type-2 diabetes who used one of these SGLT2 diabetes drugs and developed ketoacidosis or kidney failure, as well as when these diabetics suffer a heart attack (MI), stroke (CVA), or heart failure.[Read this article in full at original source]
Invokana / Farxiga / Jardiance
Free Case Evaluation
Strictly Confidential, No Obligation.